Replication of LC–MS untargeted lipidomics results in patients with calcific coronary disease: An interlaboratory reproducibility study

International Journal of Cardiology

Volumn 222, Issue , 2016, Pages 1042-1048

  Djekic, Demir ^a   Pinto, Rui ^b   Vorkas, Panagiotis A ^c   Henein, Michael Y ^a  

^a Heart Centre   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Calcific coronary disease; Coronary artery disease; Lipidomics; Metabolomics; Reproducibility

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; NITRATE; PHOSPHATIDYLCHOLINE; SPHINGOMYELIN; LIPID;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY CALCIUM SCORE; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; FEMALE; HUMAN; LIPIDOMICS; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; METABOLOMICS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; SMOKING; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; AGED; BLOOD; BLOOD VESSEL CALCIFICATION; DIAGNOSTIC IMAGING; LABORATORY TECHNIQUE; MIDDLE AGED; PROCEDURES; STANDARDS;

AGED; CHROMATOGRAPHY, LIQUID; CLINICAL LABORATORY TECHNIQUES; CORONARY ARTERY DISEASE; FEMALE; HUMANS; LIPIDS; MALE; MASS SPECTROMETRY; METABOLOMICS; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; VASCULAR CALCIFICATION;

EID: 84982192130     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.07.214     Document Type: Article

References (53)

1. [1] Nicoll, R., Henein, M., Extensive coronary calcification: a clinically unrecognised condition. Curr. Vasc. Pharmacol. 8:5 (2010), 701–705.
2. [2] Kronmal, R.A., McClelland, R.L., Detrano, R., Shea, S., Lima, J.A., Cushman, M., et al. Risk factors for the progression of coronary artery calcification in asymptomatic subjects: results from the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 115:21 (2007), 2722–2730.
3. [3] Rennenberg, R.J., Kessels, A.G., Schurgers, L.J., van Engelshoven, J.M., de Leeuw, P.W., Kroon, A.A., Vascular calcifications as a marker of increased cardiovascular risk: a meta-analysis. Vasc. Health Risk Manag. 5:1 (2009), 185–197.
4. [4] Qamar, A., Khetarpal, S.A., Khera, A.V., Qasim, A., Rader, D.J., Reilly, M.P., Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics. Arterioscler. Thromb. Vasc. Biol. 35:8 (2015), 1880–1888.
5. [5] Schmermund, A., Achenbach, S., Budde, T., Buziashvili, Y., Förster, A., Friedrich, G., et al. Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial. Circulation 113:3 (2006), 427–437.
6. [6] Henein, M.Y., Owen, A., Statins moderate coronary stenoses but not coronary calcification: results from meta-analyses. Int. J. Cardiol. 153:1 (2011), 31–35.
7. [7] Henein, M., Granåsen, G., Wiklund, U., Schmermund, A., Guerci, A., Erbel, R., et al. High dose and long-term statin therapy accelerate coronary artery calcification. Int. J. Cardiol. 184 (2015), 581–586.
8. [8] Anand, D.V., Lim, E., Darko, D., Bassett, P., Hopkins, D., Lipkin, D., et al. Determinants of progression of coronary artery calcification in type 2 diabetes role of glycemic control and inflammatory/vascular calcification markers. J. Am. Coll. Cardiol. 50:23 (2007), 2218–2225.
9. [9] Greif, M., Arnoldt, T., von Ziegler, F., Ruemmler, J., Becker, C., Wakili, R., et al. Lipoprotein (a) is independently correlated with coronary artery calcification. Eur. J. Intern. Med. 24:1 (2013), 75–79.
10. [10] Aryan, M., Kepez, A., Atalar, E., Hazirolan, T., Haznedaroglu, I., Akata, D., et al. Association of plasma osteopontin levels with coronary calcification evaluated by tomographic coronary calcium scoring. J. Bone Miner. Metab. 27:5 (2009), 591–597.
11. [11] Berezin, A.E., Kremzer, A.A., Circulating osteopontin as a marker of early coronary vascular calcification in type two diabetes mellitus patients with known asymptomatic coronary artery disease. Atherosclerosis 229:2 (2013), 475–481.
12. [12] Pérez de Ciriza, C., Moreno, M., Restituto, P., Bastarrika, G., Simón, I., Colina, I., et al. Circulating osteoprotegerin is increased in the metabolic syndrome and associates with subclinical atherosclerosis and coronary arterial calcification. Clin. Biochem. 47:18 (2014), 272–278.
13. [13] Vorkas, P.A., Isaac, G., Anwar, M.A., Davies, A.H., Want, E.J., Nicholson, J.K., et al. Untargeted UPLC-MS profiling pipeline to expand tissue metabolome coverage: application to cardiovascular disease. Anal. Chem. 87:8 (2015), 4184–4193.
14. [14] Vorkas, P.A., Isaac, G., Holmgren, A., Want, E.J., Shockcor, J.P., Holmes, E., et al. Perturbations in fatty acid metabolism and apoptosis are manifested in calcific coronary artery disease: an exploratory lipidomic study. Int. J. Cardiol. 197 (2015), 192–199.
15. [15] Gika, H.G., Theodoridis, G.A., Wingate, J.E., Wilson, I.D., Within-day reproducibility of an HPLC-MS-based method for metabonomic analysis: application to human urine. J. Proteome Res. 6:8 (2007), 3291–3303.
16. [16] Benton, H.P., Want, E., Keun, H.C., Amberg, A., Plumb, R.S., Goldfain-Blanc, F., et al. Intra- and interlaboratory reproducibility of ultra performance liquid chromatography-time-of-flight mass spectrometry for urinary metabolic profiling. Anal. Chem. 84:5 (2012), 2424–2432.
17. [17] Janowitz, W.R., Agatston, A.S., Viamonte, M., Comparison of serial quantitative evaluation of calcified coronary artery plaque by ultrafast computed tomography in persons with and without obstructive coronary artery disease. Am. J. Cardiol. 68:1 (1991), 1–6.
18. [18] Jolliffe, I.T., Principal Component Analysis. second ed., xxix, 2002, Springer, New York (487 pp.).
19. [19] Jonsson, P., Bruce, S.J., Moritz, T., Trygg, J., Sjöström, M., Plumb, R., et al. Extraction, interpretation and validation of information for comparing samples in metabolic LC/MS data sets. Analyst 130:5 (2005), 701–707.
20. [20] Crockford, D.J., Lindon, J.C., Cloarec, O., Plumb, R.S., Bruce, S.J., Zirah, S., et al. Statistical search space reduction and two-dimensional data display approaches for UPLC-MS in biomarker discovery and pathway analysis. Anal. Chem. 78:13 (2006), 4398–4408.
21. [21] Cloarec, O., Dumas, M.E., Craig, A., Barton, R.H., Trygg, J., Hudson, J., et al. Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic 1H NMR data sets. Anal. Chem. 77:5 (2005), 1282–1289.
22. [22] Wheelock, Å., Wheelock, C.E., Trials and tribulations of 'omics data analysis: assessing quality of SIMCA-based multivariate models using examples from pulmonary medicine. Mol. BioSyst. 9:11 (2013), 2589–2596.
23. [23] Martin-Ventura, J.L., Duran, M.C., Blanco-Colio, L.M., Meilhac, O., Leclercq, A., Michel, J.B., et al. Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis. Circulation 110:15 (2004), 2216–2219.
24. [24] Park, H.K., Park, E.C., Bae, S.W., Park, M.Y., Kim, S.W., Yoo, H.S., et al. Expression of heat shock protein 27 in human atherosclerotic plaques and increased plasma level of heat shock protein 27 in patients with acute coronary syndrome. Circulation 114:9 (2006), 886–893.
25. [25] De Souza, A.I., Wait, R., Mitchell, A.G., Banner, N.R., Dunn, M.J., Rose, M.L., Heat shock protein 27 is associated with freedom from graft vasculopathy after human cardiac transplantation. Circ. Res. 97:2 (2005), 192–198.
26. [26] Lepedda, A.J., Cigliano, A., Cherchi, G.M., Spirito, R., Maggioni, M., Carta, F., et al. A proteomic approach to differentiate histologically classified stable and unstable plaques from human carotid arteries. Atherosclerosis 203:1 (2009), 112–118.
27. [27] García-Arguinzonis, M., Padró, T., Lugano, R., Llorente-Cortes, V., Badimon, L., Low-density lipoproteins induce heat shock protein 27 dephosphorylation, oligomerization, and subcellular relocalization in human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 30:6 (2010), 1212–1219.
28. [28] Malaud, E., Piquer, D., Merle, D., Molina, L., Guerrier, L., Boschetti, E., et al. Carotid atherosclerotic plaques: proteomics study after a low-abundance protein enrichment step. Electrophoresis 33:3 (2012), 470–482.
29. [29] Wang, T.J., Larson, M.G., Vasan, R.S., Cheng, S., Rhee, E.P., McCabe, E., et al. Metabolite profiles and the risk of developing diabetes. Nat. Med. 17:4 (2011), 448–453.
30. [30] Newgard, C.B., An, J., Bain, J.R., Muehlbauer, M.J., Stevens, R.D., Lien, L.F., et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 9:4 (2009), 311–326.
31. [31] Fiehn, O., Garvey, W.T., Newman, J.W., Lok, K.H., Hoppel, C.L., Adams, S.H., Plasma metabolomic profiles reflective of glucose homeostasis in non-diabetic and type 2 diabetic obese African-American women. PLoS One, 5(12), 2010, e15234.
32. [32] Gall, W.E., Beebe, K., Lawton, K.A., Adam, K.P., Mitchell, M.W., Nakhle, P.J., et al. alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS One, 5(5), 2010, e10883.
33. [33] Suhre, K., Meisinger, C., Döring, A., Altmaier, E., Belcredi, P., Gieger, C., et al. Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS One, 5(11), 2010, e13953.
34. [34] Floegel, A., Stefan, N., Yu, Z., Mühlenbruch, K., Drogan, D., Joost, H.G., et al. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes 62:2 (2013), 639–648.
35. [35] Ferrannini, E., Natali, A., Camastra, S., Nannipieri, M., Mari, A., Adam, K.P., et al. Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance. Diabetes 62:5 (2013), 1730–1737.
36. [36] Würtz, P., Mäkinen, V.P., Soininen, P., Kangas, A.J., Tukiainen, T., Kettunen, J., et al. Metabolic signatures of insulin resistance in 7,098 young adults. Diabetes 61:6 (2012), 1372–1380.
37. [37] Stancáková, A., Civelek, M., Saleem, N.K., Soininen, P., Kangas, A.J., Cederberg, H., et al. Hyperglycemia and a common variant of GCKR are associated with the levels of eight amino acids in 9,369 Finnish men. Diabetes 61:7 (2012), 1895–1902.
38. [38] Mahendran, Y., Vangipurapu, J., Cederberg, H., Stancáková, A., Pihlajamäki, J., Soininen, P., et al. Association of ketone body levels with hyperglycemia and type 2 diabetes in 9,398 Finnish men. Diabetes 62:10 (2013), 3618–3626.
39. [39] Würtz, P., Havulinna, A.S., Soininen, P., Tynkkynen, T., Prieto-Merino, D., Tillin, T., et al. Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. Circulation 131:9 (2015), 774–785.
40. [40] Würtz, P., Raiko, J.R., Magnussen, C.G., Soininen, P., Kangas, A.J., Tynkkynen, T., et al. High-throughput quantification of circulating metabolites improves prediction of subclinical atherosclerosis. Eur. Heart J. 33:18 (2012), 2307–2316.
41. [41] Stegemann, C., Pechlaner, R., Willeit, P., Langley, S.R., Mangino, M., Mayr, U., et al. Lipidomics profiling and risk of cardiovascular disease in the prospective population-based Bruneck study. Circulation 129:18 (2014), 1821–1831.
42. [42] Lawton, K.A., Berger, A., Mitchell, M., Milgram, K.E., Evans, A.M., Guo, L., et al. Analysis of the adult human plasma metabolome. Pharmacogenomics 9:4 (2008), 383–397.
43. [43] Nicholson, G., Rantalainen, M., Maher, A.D., Li, J.V., Malmodin, D., Ahmadi, K.R., et al. Human metabolic profiles are stably controlled by genetic and environmental variation. Mol. Syst. Biol., 7, 2011, 525.
44. [44] Liu, L., Aa, J., Wang, G., Yan, B., Zhang, Y., Wang, X., et al. Differences in metabolite profile between blood plasma and serum. Anal. Biochem. 406:2 (2010), 105–112.
45. [45] Barri, T., Dragsted, L.O., UPLC-ESI-QTOF/MS and multivariate data analysis for blood plasma and serum metabolomics: effect of experimental artefacts and anticoagulant. Anal. Chim. Acta 768 (2013), 118–128.
46. [46] Yang, W., Chen, Y., Xi, C., Zhang, R., Song, Y., Zhan, Q., et al. Liquid chromatography-tandem mass spectrometry-based plasma metabonomics delineate the effect of metabolites' stability on reliability of potential biomarkers. Anal. Chem. 85:5 (2013), 2606–2610.
47. [47] Ammerlaan, W., Trezzi, J.P., Lescuyer, P., Mathay, C., Hiller, K., Betsou, F., Method validation for preparing serum and plasma samples from human blood for downstream proteomic, metabolomic, and circulating nucleic acid-based applications. Biopreserv. Biobank. 12:4 (2014), 269–280.
48. [48] Holland, N.T., Pfleger, L., Berger, E., Ho, A., Bastaki, M., Molecular epidemiology biomarkers—sample collection and processing considerations. Toxicol. Appl. Pharmacol. 206:2 (2005), 261–268.
49. [49] Metherel, A.H., Aristizabal Henao, J.J., Stark, K.D., EPA and DHA levels in whole blood decrease more rapidly when stored at − 20 °C as compared with room temperature, 4 and − 75 °C. Lipids 48:11 (2013), 1079–1091.
50. [50] Matyash, V., Liebisch, G., Kurzchalia, T.V., Shevchenko, A., Schwudke, D., Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics. J. Lipid Res. 49:5 (2008), 1137–1146.
51. [51] Gibney, M.J., Walsh, M., Brennan, L., Roche, H.M., German, B., van Ommen, B., Metabolomics in human nutrition: opportunities and challenges. Am. J. Clin. Nutr. 82:3 (2005), 497–503.
52. [52] Altmaier, E., Fobo, G., Heier, M., Thorand, B., Meisinger, C., Römisch-Margl, W., et al. Metabolomics approach reveals effects of antihypertensives and lipid-lowering drugs on the human metabolism. Eur. J. Epidemiol. 29:5 (2014), 325–336.
53. [53] Pechlivanis, A., Kostidis, S., Saraslanidis, P., Petridou, A., Tsalis, G., Veselkov, K., et al. 1H NMR study on the short- and long-term impact of two training programs of sprint running on the metabolic fingerprint of human serum. J. Proteome Res. 12:1 (2013), 470–480.